[go: up one dir, main page]

MXJL05000046A - Mediadores de transporte reverso de colesterol para el tratamiento de hipercolesterolemia. - Google Patents

Mediadores de transporte reverso de colesterol para el tratamiento de hipercolesterolemia.

Info

Publication number
MXJL05000046A
MXJL05000046A MXJL05000046A MXJL05000046A MXJL05000046A MX JL05000046 A MXJL05000046 A MX JL05000046A MX JL05000046 A MXJL05000046 A MX JL05000046A MX JL05000046 A MXJL05000046 A MX JL05000046A MX JL05000046 A MXJL05000046 A MX JL05000046A
Authority
MX
Mexico
Prior art keywords
hypercholesterolemia
treatment
mediators
cholesterol transport
reverse cholesterol
Prior art date
Application number
MXJL05000046A
Other languages
English (en)
Inventor
Jagadish C Sircar
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of MXJL05000046A publication Critical patent/MXJL05000046A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion proporciona composiciones adaptadas para mejorar el transporte reverso de colesterol en mamiferos. Las composiciones son adecuadas para administracion oral y utiles en el tratamiento y/o prevencion de hipercolesterolemia, aterosclerosis y enfermedades cardiovasculares asociadas.
MXJL05000046A 2003-04-22 2004-04-22 Mediadores de transporte reverso de colesterol para el tratamiento de hipercolesterolemia. MXJL05000046A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46466703P 2003-04-22 2003-04-22
PCT/US2004/012445 WO2004094471A2 (en) 2003-04-22 2004-04-22 Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia

Publications (1)

Publication Number Publication Date
MXJL05000046A true MXJL05000046A (es) 2005-12-22

Family

ID=33310929

Family Applications (1)

Application Number Title Priority Date Filing Date
MXJL05000046A MXJL05000046A (es) 2003-04-22 2004-04-22 Mediadores de transporte reverso de colesterol para el tratamiento de hipercolesterolemia.

Country Status (18)

Country Link
US (1) US20060166891A1 (es)
EP (1) EP1615954A2 (es)
JP (1) JP2007534612A (es)
KR (1) KR20050114283A (es)
CN (1) CN1809590A (es)
AR (1) AR044058A1 (es)
AU (1) AU2004233333A1 (es)
BR (1) BRPI0409609A (es)
CA (1) CA2522758A1 (es)
CL (1) CL2004000858A1 (es)
IS (1) IS8072A (es)
MX (1) MXJL05000046A (es)
NO (1) NO20055474L (es)
PE (1) PE20050136A1 (es)
RU (1) RU2005135139A (es)
TW (1) TW200503747A (es)
UY (1) UY28282A1 (es)
WO (1) WO2004094471A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006146479A (ru) * 2004-06-09 2008-07-20 Аванир Фармасьютикалс (Us) Небольшие молекулярные медиаторы для лечения гиперхолестеринемии и связанных заболеваний
AR049081A1 (es) * 2004-06-09 2006-06-21 Avanir Pharmaceuticals Mediadores del transporte inverso de colesterol para el tratamiento de la hipercolesterolemia
US20060009487A1 (en) * 2004-06-09 2006-01-12 Sircar Jagadish C Heterocyclic derivatives for treatment of hyperlipidemia and related diseases
WO2006049597A1 (en) * 2004-10-27 2006-05-11 Avanir Pharmaceuticals Amino acid-derived compounds as modulators of the reverse cholesterol transport
WO2007055873A2 (en) * 2005-11-04 2007-05-18 Avanir Pharmaceuticals Process for the manufacture of peptide facilitators of reverse cholesterol transport
ATE540681T1 (de) 2006-06-26 2012-01-15 Amgen Inc Verfahren zur behandlung von atherosklerose
EP2234493A4 (en) * 2007-12-21 2011-05-25 Univ Cincinnati THERAPEUTIC USE OF CARBOXYLESTERLIPASE INHIBITORS
GB0918579D0 (en) * 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
WO2011079214A1 (en) * 2009-12-23 2011-06-30 Artery Therapeutics, Inc., Diagnosis and treatment of reverse cholesterol transport deficiency-related diseases
US20110288017A1 (en) * 2010-03-01 2011-11-24 Leslie Frost Apo-lipoprotein propeptide
CA3026037A1 (en) 2016-05-31 2017-12-07 Institut De Cardiologie De Montreal A co-culture system and method for in vitro assessment of reverse cholesterol transport
CN113412258A (zh) 2019-01-18 2021-09-17 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法
WO2025024564A1 (en) * 2023-07-24 2025-01-30 The Board Of Regents Of The University Of Texas System Small molecules that prevent statin-induced accumulation of hmg coa reductase

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE437153B (sv) * 1976-12-01 1985-02-11 Kabi Ab Specifika kromogena enzymsubstrat for serinproteaser
US4448715A (en) * 1981-11-02 1984-05-15 University Of Miami Tagged pyroglu-L-Phe-L-Arg derivatives, substrates and assays for kallikrein
US4643988A (en) * 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
DE3781263T2 (de) * 1986-12-15 1993-04-08 Inst Nat Sante Rech Med Peptid-derivate und deren verwendung in der therapie.
US4952562A (en) * 1989-09-29 1990-08-28 Rorer Pharmaceutical Corporation Anti-thrombotic peptides and pseudopeptides
WO1999003880A1 (en) * 1997-07-15 1999-01-28 Novo Nordisk A/S Nociceptin analogues
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6821774B1 (en) * 1999-06-18 2004-11-23 Cv Therapeutics, Inc. Compositions and methods for increasing cholesterol efflux and raising HDL using ATP binding cassette transporter ABC1
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
EP2343317A1 (en) * 2000-11-10 2011-07-13 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
US20040003418A1 (en) * 2001-04-10 2004-01-01 Aya Jakobovits Nucleic acid and corresponding protein entitled 158P3D2 useful in treatment and detection of cancer

Also Published As

Publication number Publication date
KR20050114283A (ko) 2005-12-05
AU2004233333A1 (en) 2004-11-04
CL2004000858A1 (es) 2005-04-22
BRPI0409609A (pt) 2006-04-18
TW200503747A (en) 2005-02-01
IS8072A (is) 2005-10-13
WO2004094471A2 (en) 2004-11-04
NO20055474D0 (no) 2005-11-18
PE20050136A1 (es) 2005-04-20
EP1615954A2 (en) 2006-01-18
RU2005135139A (ru) 2007-05-27
CA2522758A1 (en) 2004-11-04
UY28282A1 (es) 2004-11-30
CN1809590A (zh) 2006-07-26
AR044058A1 (es) 2005-08-24
JP2007534612A (ja) 2007-11-29
US20060166891A1 (en) 2006-07-27
NO20055474L (no) 2006-01-23
WO2004094471A3 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
TW200510416A (en) P38 inhibitors and methods of use thereof
WO2004052280A3 (en) Anti-angiogenic compounds and their use in cancer treatment
EP2332527A3 (en) Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases
LUC00065I1 (es)
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2006024018A3 (en) Compositions for treating nociceptive pain
MXJL05000046A (es) Mediadores de transporte reverso de colesterol para el tratamiento de hipercolesterolemia.
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
ZA200701629B (en) Gyrase inhibitors and uses thereof
MY134480A (en) 4-pyrrolidino-phenyl-benzyl ether derivatives
NO20070139L (no) Heterosykliske derivater for behandling av hyperlipidemi og relaterte sykdommer
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
MXPA05010330A (es) Formulaciones de cladribina para el mejor suministro oral y a traves de la mucosa.
WO2004041158A3 (en) Rifalazil compositions and therapeutic regimens
WO2006034001A3 (en) Methods of treating hiv infection
AP2006003557A0 (en) Antimalarial compositions and process thereof.
TW200603795A (en) Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
TW200603794A (en) Small molecules for treatment of hypercholesterolemia and related diseases
ZA200502464B (en) Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome.
TR201900241T4 (tr) Vasoprotektif maddelerin kombinasyonları ve bunları içeren formülasyonlar.
AU2003270202A1 (en) Pharmaceutical compositions increasing camp useful for the treatment of cancers
WO2004096848A8 (en) Novel composition and methods for the treatment of immune disorders
TW200700384A (en) Amorphous tegaserod maleate
TW200801033A (en) Process for the manufacture of peptide facilitators of reverse cholesterol transport
TW200635580A (en) Methods of treatment and prevention

Legal Events

Date Code Title Description
FA Abandonment or withdrawal